The omens look good for the upcoming Pulsar readout, but can Eylea keep its wet AMD stranglehold?
Kodiak, Biomarin and Argenx prepare for clinical catalysts.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
But data are early, and other groups are also developing less frequent injections for wet AMD.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Heightened Beovu safety concerns could turn into a big problem for Novartis, while rival Regeneron will make the most of any uncertainty.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.